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Summary
For patients with chronic myeloid leukaemia (CML), treat-
ment guidelines recommend monitoring response to treat-
ment with tyrosine kinase inhibitors (TKIs) by testing the
BCR-ABL1 fusion gene transcript level using reverse tran-
scriptase quantitative polymerase chain reaction. Despite
recent efforts to standardise protocols for BCR-ABL1 testing,
some variability remains among laboratories in the UK
regarding the techniques used and the approach to reporting
results. This increases the risk of misinterpretation of results
by both clinicians and patients. An expert panel met to discuss
current issues surrounding BCR-ABL1 testing in the UK and
to develop guidance for laboratories, with emphasis on the
optimal approach to reporting laboratory results. Topics
included the minimum required information to include in the
laboratory report, units of measurement, test sensitivity and
BCR-ABL1 transcript variants. To aid communication between
laboratories and clinics, standard forms were generated that
could be used by (i) clinics when submitting samples to labo-
ratories, and (ii) laboratories when reporting results to clinics.
Standardising the way in which BCR-ABL1 test results are
reported from laboratories to clinics should help to improve
communication, interpretation of results and patient care.
Keywords: chronic myeloid leukaemia, BCR-ABL1, labora-
tory assay, laboratory report, United Kingdom.
Molecular testing for the fusion gene BCR-ABL1 is the most
sensitive routine test for monitoring response to therapy in
patients with chronic myeloid leukaemia (CML) (Foroni
et al, 2011). The technique utilises reverse transcriptase
quantitative polymerase chain reaction (RT-qPCR) to esti-
mate the amount of BCR-ABL1 mRNA relative to an internal
reference gene (typically ABL1, GUSB, or BCR) (Cross et al,
2015). Results are expressed on the International Scale (IS)
as a percentage relative to the standardised baseline used in
the pivotal IRIS (International Randomized Study of Inter-
feron and STI571) trial, which evaluated the tyrosine kinase
inhibitor (TKI) imatinib in patients with CML (Hughes et al,
2003, 2006; Cross et al, 2015). BCR-ABL1 testing is used to
define molecular response (MR) to TKIs, and a major molec-
ular response (MMR) is defined as a 3-log reduction from
the standardised baseline (MR3 or 01% BCR-ABLIS) (Bac-
carani et al, 2013). Beyond MMR, deep molecular responses
(DMRs) of MR4, MR45, and MR5 are defined as ≤001%,
≤00032%, and ≤0001% BCR-ABLIS, respectively (Table I)
(Cross et al, 2015).
As described in the current European LeukaemiaNet
(ELN) CML recommendations (Baccarani et al, 2013), regu-
lar ongoing BCR-ABL1 testing provides essential informa-
tion required to make timely important treatment
decisions, such as whether to continue current TKI, or
switch to a different TKI or alternative therapy. More
recently, the National Comprehensive Cancer Network
(NCCN) and European Society of Medical Oncology
(ESMO) guidelines have been updated to include recom-
mendations on stopping TKI treatment in patients who
have achieved a sustained DMR on TKI treatment, initiat-
ing a period of treatment-free remission (TFR) (Hochhaus
et al, 2017; NCCN, 2017). The feasibility of TFR following
achievement of DMR has been demonstrated in numerous
clinical studies (reviewed in Saussele et al, 2016; Rea &
Cayuela, 2017). However, across these studies, approxi-
mately 50% of patients had molecular recurrence (loss of
MMR) during discontinuation and required TKI re-initia-
tion. Patients who re-initiated treatment remained sensitive
to TKI treatment, and re-achieved DMR in the majority of
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cases. Molecular recurrence generally occurred within
6 months following discontinuation, although more recent
studies show later molecular recurrence continues to occur
(Campiotti et al, 2017). Thus, while all CML patients on
TKI treatment require ongoing regular BCR-ABL1 monitor-
ing, patients entering TFR require increased frequency of
monitoring of BCR-ABL1 levels (Hochhaus et al, 2017;
NCCN, 2017). This will likely increase laboratory workload
and highlights the need for fast and reliable BCR-ABL1 test
results that are effectively communicated between the labo-
ratory and clinician.
To ensure accurate BCR-ABL1 testing, laboratories
should participate in standardisation and external quality
assessment programmes, establish conversion factors or use
calibrated kits for reporting on the IS, determine the vari-
ability of their assay at high and low levels of disease (Bran-
ford & Hughes, 2006; Branford et al, 2008), and validate
that their assay is capable of detecting MR45 in most
patient samples. To assist accurate interpretation of BCR-
ABL1 results in the clinic, reports should be easily inter-
pretable and use standardised definitions of MR (Cross
et al, 2015). Despite efforts to standardise procedures (For-
oni et al, 2011; Cross et al, 2015), some variability remains
among laboratories in the UK regarding technique and
reporting results of BCR-ABL1 testing (Foroni et al, 2011),
which underscores the need for further standardisation of
protocols.
In June 2017, an expert panel met in London to discuss
potential alignment on BCR-ABL1 reporting in the UK. The
purpose of the meeting was to develop guidance to support
the accurate communication of BCR-ABL1 molecular moni-
toring results from laboratories to clinics, to enable optimal
management of patients with CML. Topics for discussion
included laboratory requirements for accurate BCR-ABL1
reporting (such as use of standardised definitions to present
results of BCR-ABL1IS, MR45, transcript type, etc.), fre-
quency of testing, the minimum clinical information that a
laboratory needs in order to provide results and accurate
response interpretation, the minimum information that
should be included in the laboratory report and additional
laboratory considerations for molecular monitoring require-
ments during TFR.
Laboratory requirements for providing an
optimal report
According to the ELN CML recommendations, molecular
testing to determine BCR-ABL1 transcript level is recom-
mended for patients with CML treated with TKIs to establish
the level of response and to monitor changes over time (Bac-
carani et al, 2013). In addition, it may be useful to quantify
BCR-ABL1 levels prior to starting therapy to determine the
velocity of response at 3 months, which can help identify
patients at risk of treatment failure (Branford et al, 2014;
Hanfstein et al, 2014).
Depending on local circumstances, patients can be moni-
tored using molecular tests, such as RT-qPCR, cytogenetic
tests, such as G-band analysis or fluorescence in situ
hybridization (FISH), or both (Baccarani et al, 2013). When
using molecular tests, it is recommended to use standardised
sensitive assays capable of detecting MR45 on the IS, because
these allow for accurate response monitoring during TKI
treatment and during TFR. Furthermore, IS results are neces-
sary for comparing patient results with the ELN recommen-
dations and data from clinical trials.
Before initiating therapy, the BCR-ABL1 transcript vari-
ant type should be determined in all patients so that molec-
ular testing can target the correct subtype and false-negative
results can be excluded (Foroni et al, 2011). Identification
of the individual transcript type is also important as this
may correlate with clinical outcome (Claudiani et al, 2017).
Standard BCR-ABL1 testing and reporting in IS units can
only be applied reliably in patients with typical transcript
variants (e13a2 and/or e14a2), which account for 97–98%
of CML patients (Foroni et al, 2011). For patients with
atypical variants, bespoke assays that target the correct vari-
ant can be used to monitor general trends in disease levels
on treatment. This may be used to inform clinical manage-
ment, but the results cannot be expressed on the IS. Given
that these patients with atypical variants are so rare, we
consider that these bespoke monitoring assays should be
carried out by specialised laboratories or ideally a single
central laboratory. However, it is essential that all laborato-
ries should be able to detect atypical variants in patients
before treatment, in order to provide faster and comprehen-
sive in-house testing results.
For patients achieving TFR, molecular monitoring is a
critical part of care to identify a potential loss of MR3, neces-
sitating restarting of TKI treatment. From the laboratory per-
spective, TFR presents many challenges: more frequent
monitoring is required and the need for rapid results with a
2-week turnaround will probably increase laboratory work-
load. Patients entering TFR have very low or undetectable
BCR-ABL1 levels, and laboratories monitoring these patients
must ensure that they are capable of detecting MR45, using
Table I. Molecular response in patients with CML: BCR-ABL1 tran-
script levels according to the International Scale (Baccarani et al,
2014; Cross et al, 2015).
BCR-ABLIS, %
Log reduction
from standardised
baseline MR category
Minimum
number of
ABL1 transcripts
100 0 – –
≤01 3 MR3 (MMR) >10 000
≤001 4 MR4 10 000–31 999
≤00032 45 MR45 32 000–99 999
≤0001 5 MR5 ≥100 000
CML, chronic myeloid leukaemia; MMR, major molecular response;
MR, molecular response.
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regular external or internal validation, and reporting on the
IS to ensure DMR can be accurately monitored prior to
and during TKI discontinuation. Due to the requirement
for standardised results reported on the IS prior to and
during TFR, treatment discontinuation is currently only
recommended in patients with typical transcripts and
where IS results are available (NCCN, 2017). In addition,
regular monitoring of patients in long-term TFR will
require careful coordination between the laboratory and
haematologist/oncologist to ensure that reintroduction of
treatment in the case of molecular recurrence can be
started promptly.
BCR-ABL1 kinase domain point mutations reflect disease
evolution and may be used to inform subsequent therapy
(Soverini et al, 2011). Therefore, mutational analysis is rec-
ommended in case of disease progression and treatment fail-
ure, and for patients in the ELN ‘Warning’ response category
(Baccarani et al, 2013). According to the ELN recommenda-
tions (Baccarani et al, 2013), mutational analysis should be
performed using Sanger sequencing until the clinical rele-
vance of mutations detected with more sensitive techniques
has become clear.
Frequency of monitoring
International treatment guidelines are generally consistent
with regard to the frequency of BCR-ABL1 testing when
monitoring response to TKIs. The ELN recommends testing
every 3 months until BCR-ABL1 ≤ 01%IS (MMR) is
achieved and then every 3–6 months thereafter (Baccarani
et al, 2013). In the American NCCN guidelines, testing is
recommended at diagnosis, every 3 months after starting
treatment until BCR-ABL1 01–1%IS is achieved, then every
3 months for 2 years, and every 3–6 months thereafter
(NCCN 2017).
The ELN CML recommendations include response cate-
gories (Optimal, Warning and Failure) and monitoring fre-
quency requirements for patients receiving TKIs as first-line
(Table II) or second-line treatment in the case of failure to
first line imatinib (Baccarani et al, 2013). If a patient falls in
the ‘Failure’ category, they should initiate a different treat-
ment (e.g. an alternative TKI or allogeneic stem cell trans-
plant) in order to decrease the risk of disease progression
and mortality. In addition, cytogenetic analysis of marrow
cell metaphases, RT-qPCR and, when appropriate, muta-
tional analysis should be performed. In some cases, repeat
testing on the same sample, if possible, may be required. If a
test result is significantly different from the previous result,
the test should be repeated within the laboratory before
being reported. If the result remains significantly different,
the clinician should be notified and arrangements should be
made for the patient to return for repeat sampling. It should
be noted that repeat sampling can cause anxiety in patients;
efforts to minimise distress regarding repeat testing should
be considered.
How to report: clinician to laboratory
Good communication among members of the multidisci-
plinary team is essential for supporting good communication
between the clinician and patient, thus ensuring more effec-
tive disease management (Fig 1). This includes submitting
5.  When results are shared with patient:
BCR-ABL1 level
These should include only the
Contact clinician in case of
most relevant information,
such as the 
concerns about test results
4.  Laboratory reports test results to
Highlight marked increases in
BCR-ABL1 transcript level and/or
loss of molecular response
3.  Laboratory analyses BCR-ABL1
Prepares laboratory report and
initial interpretation
1.  Patient reports to treating
Assessment
Sample collection
2.  Clinician submits sample 
clinician and/or multidisciplinary
team transcript level
clinician
to laboratory for analysis
Includes relevant patient 
and treatment information
Fig 1. Patterns of communication among the CML healthcare team regarding BCR-ABL1 testing. CML, chronic myeloid leukaemia. *Multidisci-
plinary team: including pharmacy.
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sufficient clinical information with blood samples, and pro-
viding a comprehensive yet practical laboratory report. Cur-
rently, samples are often submitted for BCR-ABL1 testing
without sufficient clinical information about the patient,
leading to difficulty in providing an interpretative labora-
tory report (Claustres et al, 2014). Although providing brief
clinical details with a BCR-ABL1 test request can be chal-
lenging within the context of a busy clinic, this information
is important to ensure good laboratory–clinician communi-
cation. To reduce workload, some laboratories have devel-
oped CML-specific online forms that clinicians can fill out
when submitting samples, and this approach is encouraged.
Ideally, the following clinical information should be submit-
ted to the laboratory: TKI therapy and any recent known
treatment interruptions (e.g. pregnancy, TFR, intolerance)
and possible issues with treatment adherence. For patients
Fig 2. Information to accompany samples submitted for BCR-ABL1 testing. NHS, National Health Service; TKI, tyrosine kinase inhibitor.
Review
ª 2018 The Authors. British Journal of Haematology published by John Wiley & Sons Ltd
on behalf of British Society for Haematology. British Journal of Haematology, 2018, 182, 777–788
781
who are being transferred between hospitals, BCR-ABL1
transcript type and, in cases where resistance has been
encountered, TK domain mutation status should be
reported as well. Sample forms are shown in Figs 2 and 3.
Various aspects of the clinician’s report are discussed in
more detail below.
Additional mutation analysis?
Hb WBC Pits
TKI treatment line number
Requested by
Contact details
Any other CML treatment
Additional mutation analysis?Lymphs Neut Other
full name required
venous blood
Sample ref
Patient/unit number
Previous BCR-ABL1 results
Any other CML treatment
Specimen type(s)
Referring hospital
Reg. number: ††††††††††
please check and amend if necessary
All highlighted fields are required
Matching patient details found
******
******
optional field
Last name:
First name:
Date of birth: 1 January 1991
Gender: M
Middle name:
Select from suggestions unit (min. 4 chars)
Select from suggestions unit (min. 4 chars)Consultant
Danger of infection sample?
Microbiological or radiological evidence of TB?
Previously investigated by HMDS?
Any other CML treatment
Additional mutation analysis?
TKI treatment line number
Current TKI treatment
Phase of disease
Current TKI treatment
TKI treatment line number
dd/mm/yyyy
Select any combination
Select any combination
list other treatment(s) here
Date of diagnosis
– select –
– select –
– select –
chronic phase
accelerated phase
blast crisis
Phase of disease
Current TKI treatment
TKI treatment line number
Validate
– select –
– select –
– select –
1st line
2nd line
3rd line
> 3rd line
– select –
– select –
imatinib
dasatinib
nilotinib
ponatinib
bosutinib
none
– select –
None
F U
Yes No
Yes No
No UnknownYes
Fig 3. Screenshot of an online request form for BCR-ABL1 testing. CML, chronic myeloid leukaemia; F, female; Hb, haemoglobin; HMDS, Hae-
matological Malignancy Diagnostic Service; Lymphs, lymphocytes; M, male; Neut, neutrophils; Plts, platelets; TB, tuberculosis; TKI, tyrosine
kinase inhibitor; U, unknown; WBC, white blood cells.
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Clinical details
Accurate clinical details are essential in order to offer appro-
priate clinical guidance for patients receiving TKI therapy.
Bespoke online request forms offer an attractive means to
achieve this. Linked to a departmental laboratory information
management system, patient demographics can be populated
using the National Health Service (NHS) number following a
patient’s initial registration on the system, usually at diagnosis.
Additional disease and treatment information can then be
added using a simple drop-down menu each time the patient
attends the clinic for molecular monitoring. Phase of disease,
line of therapy and current TKI usage can all be captured on
the form, making informed clinical interpretation possible.
Dose escalation, modification, and cessation of TKI can also
be documented in a similar manner on the request form. If
clinical details are not available, laboratory reports should
clearly state that interpretation of the results according to ELN
recommendations is not possible.
Therapy
Samples submitted for BCR-ABL1 testing should include
the line of therapy of TKI treatment, which is essential to
provide ELN response category as part of the report, and
should be included in the laboratory report whenever pos-
sible. Changes in treatment can influence the interpreta-
tion of results, and the laboratory should be informed of
any significant changes to treatment, including switching
to a different TKI, treatment interruptions or discontinua-
tion.
Timing of sample in relation to start of TKI therapy
If available, including the sample time point (e.g. 3 months
after starting TKI) is essential for the interpretation of
results. If this information is not provided with the sample,
it may be found in electronic regional prescribing systems, if
available.
How to report: laboratory to clinician
The following minimum required information should be
included in the molecular genetics laboratory report: patient
and physician information, test performed, test result and
broad interpretation to help guide the final interpretation
by the referring clinician, and any relevant supplemental
information (Scheuner et al, 2012; Claustres et al, 2014). A
sample laboratory report is shown in Fig 4, and examples
of laboratory reports illustrating various clinical scenarios
are shown in Appendix S1 (Figures S1–S4). Various aspects
of the laboratory report are discussed in more detail
below.
BCR-ABL1 transcript variants
As discussed above, the BCR-ABL1 transcript variant type
should be established at the time of diagnosis to determine
the most appropriate method for monitoring changes in
BCR-ABL1 transcript level (Foroni et al, 2011). Variant type
has important implications, not only for testing protocols
but also for treatment decisions. For example, stopping
nilotinib in patients who have achieved sustained DMR is
currently only recommended for patients with confirmed
typical variants (i.e. e13a2 and e14a2) (www.ema.europa.e
u/docs/en_GB/document_library/EPAR_-_Product_Informa
tion/human/000798/WC500034394.pdf; Hochhaus et al,
2017; NCCN 2017). Therefore, the variant type should be
included in the laboratory report and atypical variants
should be highlighted.
Cumulative timeline of BCR-ABL1 transcript level
A list or graph describing previous test results is strongly
recommended to present results over time to allow the clin-
ician to easily interpret the current result in the context of
previous results. Ideally a graph should include some indi-
cation of the limit of detection of the assay and ELN
response category. This interpretation would mandate the
date of TKI initiation and line of therapy to be stated.
Examples of such graphs are given in Appendix S1 (Figures
S1–S4).
TK domain mutations
Ideally, a timeline graph should be generated indicating the
time points at which mutation analysis was carried out, the
type of mutation(s) present (using Human Genome Varia-
tion Society [HGVS] nomenclature; see http://varnomen.
hgvs.org) and the time point at which each mutation was
first detected, as well as the sensitivity of mutation detec-
tion, the level of the mutation, and a brief summary of
whether it is likely to be sensitive or resistant to other
TKIs.
Units
All laboratories should report results using the IS (Hughes
et al, 2006). Unconverted results should only be included
Expert panel opinion
• Ideally, when submitting samples for BCR-ABL1 testing,
clinicians should provide the following information: line
of therapy, start date for current TKI, and any recent
treatment interruptions (e.g. pregnancy, TFR)
• Laboratories should be informed of whether the
patient is in TFR and date of treatment cessation as
this can affect the frequency of monitoring
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during a transition phase to IS, as routine reporting of
unconverted results can lead to misinterpretation of ELN
response by clinicians. At this time, not all laboratories in
the UK report BCR-ABL1 results using the IS, and some lab-
oratories are currently transitioning to the IS system. If units
other than IS are used, the laboratory report should state
clearly that the results are not reported in IS. Transitioning
requires good communication with clinicians and patients. It
is essential that patients are adequately counselled about the
change to IS, so that they are not unduly alarmed by a
marked change in their test results.
Reference gene
The laboratory report should mention which reference gene
(ABL1, GUSB or BCR) was used.
Test sensitivity
For patients with undetectable BCR-ABL1 levels, it is impor-
tant to state the level at which BCR-ABL1 is undetectable (e.g.
MR4 vs. MR45). In the laboratory report, placing the result in
context by including standard levels of response (MMR, MR4,
MR45) may aid clinicians. Efforts to establish confidence
intervals are under way at individual laboratories, but there is
no consensus on how to report this information at this time.
Nevertheless, testing laboratories need to understand their
measurement uncertainty at high and low BCR-ABL1 levels
(Branford & Hughes, 2006; Branford et al, 2008).
Technique used
Technical details, such as the level of sensitivity and method-
ology used, should also be included in the laboratory report.
Fig 4. Standard laboratory report for BCR-ABL1 testing. CML, chronic myeloid leukaemia; ELN, European LeukaemiaNet; ID, identification; IS,
International Scale; MR, molecular response; TKI, tyrosine kinase inhibitor.
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Response status (MMR, MR4, MR45)
Laboratory reports should include both the actual BCR-ABL1
result (e.g. 008%) and the corresponding response status
(e.g. MMR) to aid in interpretation.
Response status according to ELN CML
recommendations
The current ELN recommendations include three response cate-
gories (Optimal, Warning and Failure) (Baccarani et al, 2013).
In some cases, laboratories may not have access to sufficient
clinical information to determine response status according to
the ELN recommendations. If the information is available, inter-
pretation of results according to the current ELN recommenda-
tions could be a useful addition to the laboratory report. As a
minimum, a reference to the ELN recommendations for clinical
interpretation should be provided on the report.
Suggestions for frequency of testing
Frequency of monitoring should be as per current ELN rec-
ommendations (see Table II). The laboratory should promptly
notify the clinician and/or other members of the multidisci-
plinary team when there is a significant increase in BCR-ABL1
level and/or when a change in monitoring frequency is
required. What constitutes a significant change needs to be
defined locally on the basis of the level of disease and the
uncertainty of measurement of the assay used, but in general
a 1-log increase or loss of MMR in a patient with previous
stable MMR would be considered as a significant change. Any
change reported as potentially significant should be confirmed
before making any alterations to management, and the labora-
tory report should contain appropriate caveats plus a request
for an urgent repeat sample. A laboratory may suggest a
change in testing frequency, but it should be noted that the
suggestion may be incorrect if the laboratory is provided with
incomplete or inaccurate clinical information (see below).
Date of next test
Providing or suggesting a date for the next test may be useful
but is considered optional, because the laboratory may not
have sufficient clinical information to determine the date of
the next test. If a patient misses a visit, it may be useful for
laboratories to have standard procedures in place to alert the
multidisciplinary team so that the patient can be contacted.
While this is not normally the laboratory’s responsibility, this
could help ensure that patients are followed appropriately.
How to report: patient-directed communication
Increasingly, patients have access to laboratory results, and com-
plex or poorly worded reports can lead to unnecessary alarm
and confusion. The UK government has made a commitment
that patient clinical records will be digitalised and accessible
to patients and healthcare providers in real time by 2020.
If reports are being sent to the patient, these should contain
the most important information only, such as the BCR-ABL1
level and whether the level has increased, decreased or
remained stable since the last test, as shown in Fig 5. Their
current test result should be contextualised by including their
two previous BCR-ABL1 testing results. It would also be
Expert panel opinion
The laboratory report should ideally include the
following:
• Transcript variant type
• Line of therapy
• Results reported in IS only
– If units other than IS are currently used, it should
be clearly stated in the laboratory report that
results are not reported in IS
– Unconverted results should only be included dur-
ing a transition phase to IS
• Reference gene used (ABL1, GUSB, or BCR)
• Technical details, such as the level of sensitivity
• Both the actual BCR-ABL1 result (e.g. 008%) and the
corresponding response status (e.g. MMR)
– Laboratory results should be interpreted in the
context of prior results, response status, and clini-
cal circumstances
– Results should be interpreted according to the cur-
rent ELN recommendations
• The laboratory should promptly notify the clinician
and/or multidisciplinary team when there is a marked
change in BCR-ABL1 level and/or when a change in
monitoring frequency is required. What constitutes a
‘marked’ change needs to be defined locally on the
basis of the level of disease and the measured variation
of the essay used, but in general a 1-log increase or
loss of MMR would be considered as a marked change
– Changes to monitoring frequency should be finalised
after the laboratory has consulted with the treating
haematologist/oncologist; this is usually determined
by the clinician rather than the laboratory
If available, the laboratory report could also include the
following:
• Mutation status and the time at which the mutation
was first detected (including details of TKI sensitivity)
• Timing of the test in relation to the start of TKI (e.g.
3 months after start of TKI)
• A list or graph describing previous BCR-ABL1 test
results is strongly recommended
• Suggesting a date for the next test is considered optional
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Fig 5. Standard patient-directed report of BCR-ABL1 testing results.
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important to indicate to patients if the sample had been a tech-
nical failure or not, if a result cannot be given. A comment
could be added to the report that the patient should contact
their clinician if they have a concern about their test results.
Concluding remarks
The remarkable improvements in outcomes observed in
patients with CML in recent years have occurred in tandem
with advances in molecular monitoring of the disease. How-
ever, considerable variability persists among laboratories in
the UK regarding testing methods and reporting results for
BCR-ABL1 transcript levels. This consensus report provides a
framework for developing a more standardised approach to
presenting BCR-ABL1 results. This will hopefully encourage
greater uniformity across laboratories in the UK and support
the accurate translation of results from laboratory to clinic,
which is essential for the delivery of optimal CML patient
care and disease management.
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